These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24505287)

  • 1. Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients.
    Knudsen S; Jensen T; Hansen A; Mazin W; Lindemann J; Kuter I; Laing N; Anderson E
    PLoS One; 2014; 9(2):e87415. PubMed ID: 24505287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.
    Patani N; Dunbier AK; Anderson H; Ghazoui Z; Ribas R; Anderson E; Gao Q; A'hern R; Mackay A; Lindemann J; Wellings R; Walker J; Kuter I; Martin LA; Dowsett M
    Clin Cancer Res; 2014 Aug; 20(15):3962-73. PubMed ID: 24916694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
    Rao X; Di Leva G; Li M; Fang F; Devlin C; Hartman-Frey C; Burow ME; Ivan M; Croce CM; Nephew KP
    Oncogene; 2011 Mar; 30(9):1082-97. PubMed ID: 21057537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
    Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.
    Jeselsohn R; Barry WT; Migliaccio I; Biagioni C; Zhao J; De Tribolet-Hardy J; Guarducci C; Bonechi M; Laing N; Winer EP; Brown M; Leo AD; Malorni L
    Clin Cancer Res; 2016 Dec; 22(23):5755-5764. PubMed ID: 27185372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
    Morrison MM; Hutchinson K; Williams MM; Stanford JC; Balko JM; Young C; Kuba MG; Sánchez V; Williams AJ; Hicks DJ; Arteaga CL; Prat A; Perou CM; Earp HS; Massarweh S; Cook RS
    J Clin Invest; 2013 Oct; 123(10):4329-43. PubMed ID: 23999432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
    Massarweh S; Tham YL; Huang J; Sexton K; Weiss H; Tsimelzon A; Beyer A; Rimawi M; Cai WY; Hilsenbeck S; Fuqua S; Elledge R
    Breast Cancer Res Treat; 2011 Oct; 129(3):819-27. PubMed ID: 21792626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
    Jones SE; Pippen J
    Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S9-14. PubMed ID: 15865850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.
    Zhang Q; Shao Z; Shen K; Li L; Feng J; Tong Z; Gu K; Wang X; Xu B; Sun G; Chen H; Rukazenkov Y; Jiang Z
    Oncotarget; 2016 Aug; 7(35):57301-57309. PubMed ID: 27359058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
    Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
    Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
    Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
    J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
    J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
    Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
    Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
    Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
    Zhang X; Diaz MR; Yee D
    Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.